冠心病患者TNF-a 水平及其基因多态性的研究

为了研究中国汉族人群中血清肿瘤坏死因子-a（TNF-a）水平及其-857、-863位点基因多态性与冠心病之间的相关性, 采用双抗体夹心ELISA法检测血清TNF-a水平,同时应用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）技术检测TNF-a基因多态性。 冠心病组血清TNF-a水平显著高于对照组（P<0.05）,-863 位点基因多态性在两组间分布有显著差异(P<0.05),-857位点分布无差异。血清TNF-a水平显著升高提示炎性反应在冠心病病程中有重要作用,TNF-a的水平受其基因多态性的影响。     

冠心病患者TNF-α水平及其基因多态性的研究

为了研究中国汉族人群中血清肿瘤坏死因子-α(TNF-α)水平及其-857、-863位点基因多态性与冠心病之间的相关性, 采用双抗体夹心ELISA法检测血清TNF-α水平,同时应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术检测TNF-α基因多态性. 冠心病组血清TNF-α水平显著高于对照组(P<0.05),-863 位点基因多态性在两组间分布有显著差异(P<0.05),-857位点分布无差异.血清TNF-α水平显著升高提示炎性反应在冠心病病程中有重要作用,TNF-α的水平受其基因多态性的影响.     

健康人群肿瘤坏死因子-α基因多态性的分析

了解汉族健康人群中TNF-A基因多态性的分布,研究TNF-α表达与相关疾病之间的联系。采用PCR-限制性长度片段多态分析法检测140名重庆地区汉族健康人群的TNF—A-308,TNF—A-857位点基因多态性,计算其基因型和等位基因频率,结果显示TNF-A-308G／G、G／A、4朋基因型的频率分别为89％、11％、1％,其等位基因的发生频率以G等位基因最常见（93％）,其次为A等位基因（7％）。TNF—A-857C／C、C／T、形,基因型的频率分别为68％、36％、8％,其等位基因发生频率以C等位基因最常见（81％）,其次为T等位基因（19％）。由结果可以得出重庆地区汉族健康人群TNF—A-308位点存在G／A多态性,TNF-A-857位点存在C／T多态性。     

肿瘤坏死因子α-863C／A基因多态性与慢性阻塞性肺疾病的相关性研究

目的：探讨肿瘤坏死因子α（tumor necrosis factor—α,TNF-α）-863C／A基因多态性与慢性阻塞性肺疾病（chronic obstructive pulmonary disease,COPD）间的关系。方法：采用多重聚合酶链一高温连接酶检测反应（PCR-LDR）方法研究56例吸烟COPD患者、64例吸烟正常对照组的TNF-a一863位点基因型及A等位基因的分布情况。结果：（1）吸烟COPD组在．863位点上的cA基因型及A等位基因频率均低于吸烟非COPD组（P〈0．05）。（2）重度、极重度COPD组在该位点的CA基因型频率和A等位基因频率均低于轻中度COPD组（P〈0．05）。在COPD组中携带A等位基因的患者有着更高的第1秒呼气量／用力肺活量（FEV1／FVC）和体重指数（BMI）（P〈0．05）。（3）吸烟COPD组携带CA基因型的患者肺源性心脏病的发病率高于携带CC基因型的患者（P〈0．05）。（4）吸烟COPD组的BMI[（22．0±3．1）kg／m21较吸烟非COPD组[（24．5±3．7）kg／m2]低,重度、极重度COPD组BMI[（21．2±3．0）kg／m2]较轻中度COPD组[（23.3±3．3）kg／m2]低,差异均有统计学意义（P〈0．05）。结论：TNF-α-863位点A等位基因的发生对COPD患者是一个保护性因素。低BMI与COPD关系密切,BMI可能成为预测COPD患者病情严重程度的一个重要指标。     

肿瘤坏死因子α－863C/A基因多态性与慢性阻塞性肺疾病的 相关性研究

目的:探讨肿瘤坏死因子α(tumornecrosisfactor-α,TNF-α)-863C/A基因多态性与慢性阻塞性肺疾病(chronicobstructivepulmonary disease,COPD)间的关系。方法:采用多重聚合酶链-高温连接酶检测反应(PCR-LDR)方法研究56例吸烟COPD患者、64例吸烟正常对照组的TNF-α-863位点基因型及A等位基因的分布情况。结果:(1)吸烟COPD组在-863位点上的CA基因型及A等位基因频率均低于吸烟非COPD组(P<0.05)。(2)重度、极重度COPD组在该位点的CA基因型频率和A等位基因频率均低于轻中度COPD组(P<0.05)。在COPD组中携带A等位基因的患者有着更高的第1秒呼气量/用力肺活量(FEV1/FVC)和体重指数(BMI)(P<0.05)。(3)吸烟COPD组携带CA基因型的患者肺源性心脏病的发病率高于携带CC基因型的患者(P<0.05)。(4)吸烟COPD组的BMI[(22.0±3.1)kg/m2]较吸烟非COPD组[(24.5±3.7)kg/m2]低,重度、极重度COPD组BMI[(21.2±3.0)kg/m2]较轻中度COPD组[(23.3±3.3)kg/m2]低,差异均有统计学意义(P<0.05)。结论:TNF-α-863位点A等位基因的发生对COPD患者是一个保护性因素。低BMI与COPD关系密切,BMI可能成为预测COPD患者病情严重程度的一个重要指标。     

广西地区汉族人群TNF-α基因启动子-238G/A多态性分布的研究

目的了解TNF-α基因启动子-238G/A多态性在广西地区汉族人群中的分布特点.方法应用聚合酶链反应-限制性片段长度多态性法(PCR-RFLP)检测170例正常汉族人TNF-α基因型并与其它种族的分布进行比较.结果 TNF-α基因型以GG型最为多见(95.9%),这种基因多态性分布在男女间均无显著差异(P>0.05).与其它种族比较,发现不同种族间TNF-α基因型分布及等位基因频率均存在显著差异(P<0.05).结论在广西地区汉族人群中存在TNF-α基因多态性,但在不同种族间分布有明显的差异,这种差异可能是导致一些疾病在不同种族间的发生、转归和预后不同的遗传因素之一.     

TNFa-308基因启动子多态性与新疆维吾尔族人乙型肝炎易感性的相关性研究

目的：研究TNF-α基因单核苷酸多态性（SNP）308G—A位点与新疆地区维吾尔族人乙型肝炎之间的关系。方法：以聚合酶链式反应－限制性内切酶长度多态性（PCR-RFLP）技术,对120例乙肝患者和120例正常对照者TNF—α基因SNP308多态性位点进行基因分型。结果：SNP308多态性位点G／G基因型和G／A基因型频率在病例组为77％和23％,正常对照组为88％和12％,2组基因型和等位基因频率分布差异有显著性（p〈0．05）。结论：TNF—α基因启动子308多态性位点与新疆维吾尔族人乙肝有明显相关性。     

胰岛素受体基因多态性与2 型糖尿病的相关性

目的：探讨胰岛素受体基因（INSR）的第8外显子NaiⅠ多态性与湖北汉族人群2型糖尿痛的相关性;方法：采用同胞对（家系内对照）和随机病例-对照两种实验设计,并结合聚合酶链反应-限制性片断长度多态性（PCR—RFLP）技术分析了224个样本的INSR基因第8外显子NsiⅠ多态性,并洲定了身高、体重、腰围、臀围、血压和空腹血糖等生理指标;结果：两种实验设计中对照组与病例组的基因型和基因频率均无显著差异;结论：INSR基因在湖北汉族人群2型糖屎病的发生发展中可能不起主要作用。     

肿瘤坏死因子α基因启动子区多态性与皖南地区Graves病发生的关系

目的 探讨肿瘤坏死因子α（TNF-α）基因启动子区-238G/A和-308G/A多态与皖南地区汉族人Graves病（GD）发生的关系.方法 采用Taqman探针等位基因鉴别技术,检测和分析432例Graves病患者和629例正常对照者的TNF-α基因-238G/A和-308G/A多态位点的基因型和等位基因的频率.结果 TNF-α-238G/A和-308G/A多态基因型和等位基因频率在病例组和对照组的分布均无统计学差异（P＞0.05）,根据基因型分组进行临床病理特征比较亦未发现相关性.结论 TNF-α-238G/A和-308G/A多态与皖南地区汉族人GD发病无相关性.     

中国人群中肿瘤坏死因子α-308 A/G基因多态和α2-巨球蛋白基因缺失多态与晚发性阿尔茨海默病无相关性

晚发性阿尔茨海默病 (LOAD)是老年痴呆中最常见的一种 ,它是一种病因复杂、由遗传因素和环境等其他因素共同作用引起的老年期疾病。服用非甾类抗炎类药物能延缓或防止LOAD的发病说明炎症反应可能参与LOAD病理 ,肿瘤坏死因子 (TNF)是炎症反应中主要的细胞因子 ,并且能增加 β 淀粉样肽 (Aβ)的产生说明其可能是LOAD的易感基因。α2 巨球蛋白 (A2M)是一种血清蛋白酶抑制剂 ,它是低密度脂蛋白受体相关蛋白 (LRP)主要的配体 ,并且能与Aβ结合并介导其降解和清除 ,说明它可能是另一个LOAD的易感基因。在 6 7名晚发性阿尔茨海默病人和 14 2名正常对照中比较了载脂蛋白E基因 (APOE)、TNF启动子区 (- 30 8A G)多态和A2M一 5bp核苷酸缺失 (I D)多态 (A2M 2 )与LOAD发病风险的关系。结果显示 ,APOEε4等位基因在AD病人组中显著高于对照组 (χ2=11 6 6 ,P <0 0 1) ,而TNF(- 30 8A G)多态和A2M缺失多态的基因型和等位基因在LOAD病人组和对照组中都无显著差别 (P >0 1)。按年龄和APOEε4等位基因分组同样无相关性 ,说明TNF 30 8A G位点的多态与A2M缺失不是中国人群的晚发性老年痴呆的风险因子     

Detection of anti-elongation factor 2 kinase (calmodulin-dependent protein kinase III) antibodies in patients with systemic lupus erythematosus

Elongation factor 2 kinase (eEF-2K), also known as calmodulin-dependent protein kinase III, is a member of the calmodulin-mediated signaling pathway that links activation of cell surface receptors to cell division. The activity of eEF-2K is increased in many human cancers and may be a valid target for anti-cancer treatment. It is one of the unconventional eukaryotic protein kinases with respect to its structural domains in comparison to other members of the serine/threonine protein kinase superfamily. eEF-2K is highly conserved in nature. For example, the amino acid sequence of human eEF-2K is 90% identical to mouse and rat eEF-2Ks and 40% identical to that of the C. elegans enzyme. Therefore it has been difficult to generate high-titer and high-specificity antibodies to the human enzyme by traditional techniques. Patients with systemic lupus erythematosus (SLE) produce auto-antibodies to a variety of cellular proteins, including members of the protein translation apparatus. Hence, we developed an ELISA assay that could detect anti-eEF2K antibodies from sera of SLE patients using purified eEF-2K as an antigen. We screened 117 sera from SLE patients. High-titer anti-eEF-2K antibodies were detected in 72 subjects. One of the high-titer sera was used for further characterization. The auto-antibody recognized eEF-2K on immunoblots and immunoprecipitated the kinase with intact enzyme activity. In conclusion, anti-eEF-2K antibodies are found in sera of SLE patients and are useful tools to study the role of this highly conserved enzyme.     

Tumor necrosis factor receptor superfamily members 1a and 1b contribute to exacerbation of atherosclerosis by Chlamydia pneumoniae in mice

The host immune responses that mediate Chlamydia-induced chronic disease sequelae are incompletely understood. The role of TNF-α, TNF receptor 1 (TNFR1), and TNF receptor 2 (TNFR2), in Chlamydia pneumoniae (CPN)-induced atherosclerosis was studied using the high-fat diet-fed male C57BL/6J mouse model. Following intranasal CPN infection, TNF-α knockout (KO), TNFR1 KO, TNFR2 KO, and TNFR 1/2 double-knockout, displayed comparable serum anti-chlamydial antibody response, splenic antigen-specific cytokine response, and serum cholesterol profiles compared to wild type (WT) animals. However, atherosclerotic pathology in each CPN-infected KO mouse group was reduced significantly compared to WT mice, suggesting that both TNFR1 and TNFR2 promote CPN-induced atherosclerosis.     

Predictors of clinical outcomes in patients with neuropsychiatric systemic lupus erythematosus

IntroductionNeuropsychiatric systemic lupus erythematosus (NPSLE), a serious organ disorder with a variety of symptoms, has diverse therapeutic outcomes because of the variability of NPSLE manifestations. A comprehensive association study of NPSLE among clinical and immunopathogenic aspects and outcomes has not been conducted.MethodsWe analyzed the laboratory data, NPSLE symptoms, and clinical outcomes at 1 yr post-treatment and the profiles of 27 cytokines, chemokines and growth factors in cerebrospinal fluid (CSF) samples using the Bio-Plex Human 27-plex panel from 28 NPSLE patients. Univariate and multivariable competing risks regression analyses were used to determine the predictive factors of clinical response. We also tried to predict the outcome of NPSLE by the 27 cytokines/chemokines/growth factors using a weighted-voting (WV) algorithm.ResultsOf the two males and 26 females (92.9%), 16 were non-responders at 1 yr post-treatment; in the final model, the independent predictors of non-responders were longer disease durations of SLE (odds ratio [OR]: 1.490, 95% confidence interval [CI]: 1.143–2.461, p = 0.0003) and patients with more than one NPSLE symptom types (OR: 15.14, 95% CI: 1.227–452.1, p = 0.0334). The pretreatment CSF interleukin (IL)-6, IL-10, interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) levels were significantly higher in the non-responders (p = 0.0207, p = 0.0054, p = 0.0242 and p = 0.0077, respectively). We identified six “minimum predictive markers:” IL-10, TNF-α, IL-6, IFN-γ, IL-4 and IL-13 by a WV algorithm that showed the highest accuracy (70.83%) and highest Matthews correlation coefficient (54.23%).ConclusionsWe have devised a numerical prediction scoring system that was able to separate the non-responders from responders. The patients with longer disease durations of SLE and those with more than one NPSLE symptom types had poorer outcomes. Our findings may indicate both the importance of making a diagnosis at an earlier phase for better therapeutic response and the usefulness of measuring multiple cytokines to predict NPSLE therapeutic outcomes.     

Association of vitamin D receptor gene polymorphism with the risk of systemic lupus erythematosus

Abstract

Relationship between vitamin D receptor (VDR) gene polymorphism and the risk of systemic lupus erythematosus (SLE) from the published reports are still conflicting. This study was conducted to evaluate the relationship between VDR BsmI (rs1544410), Fok1 (rs2228570), ApaI (rs7975232) and TaqI (rs731236) gene polymorphism and the risk of SLE using meta-analysis method. The association studies were identified from PubMed and Cochrane Library on 1 March 2014, and eligible investigations were included and synthesized using meta-analysis method. Thirteen reports were recruited into this meta-analysis for the association of VDR gene polymorphism with SLE susceptibility. In this meta-analysis for overall populations, the BsmI B allele and bb genotype, Fok1 f allele and ff genotype, and ApaI aa genotype, were associated with the risk of SLE. In Asians, the BsmI B allele, BB genotype and bb genotype, Fok1 f allele and ff genotype were associated with the risk of SLE. In Africans, the BsmI B allele, BB genotype and bb genotype, Fok1 f allele and ff genotype, ApaI A allele, AA genotype and aa genotype were associated with the risk of SLE. However, VDR BsmI, Fok1, ApaI and TaqI gene polymorphism were not associated with the risk of SLE in Caucasians. In conclusion, the BsmI B allele and bb genotype, Fok1 f allele and ff genotype were associated with the risk of SLE in overall populations, and in Asians, but these associations were not found in Caucasians. However, more studies should be conducted to confirm it.     

系统性红斑狼疮与肠道菌群关系研究进展

系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种慢性进行性自身免疫疾病,可累及全身多器官。SLE的发病机制不仅与遗传易感性有关,还与环境因素有关,其中肠道菌群紊乱引起了越来越多的关注。研究表明,肠道菌群是影响自身免疫性疾病发病率的环境因素。公认的机制包括异常的微生物移位、分子拟态以及局部和全身免疫的失调。因此,肠道菌群及其代谢物影响SLE的发生发展。本文将重点探讨肠道菌群与SLE的关系,以及菌群干预作为SLE防治的新策略,为进一步研究SLE的诊断和治疗提供新的思路。     

Systemic lupus erythematosus associated with primary large cell carcinoma of the lung

The association between systemic lupus erythematosus (SLE) and malignancy has been controversial in the literature. We report a case of lung cancer in a 50-year-old woman with a 4-year history of SLE. She underwent surgery at a pathological stage of T2N2M0, but she eventually died of rapid recurrence of the cancer in the abdomen resulting in massive haemorrhage from the inferior vena cava (IVC). Immunological disorders related to SLE are thought to contribute to rapid progression of the malignancy.     

Antibodies to triosephosphate isomerase in patients with neuropsychiatric lupus

Sera from patients with neuropsychiatric lupus (NP lupus) were screened for antibodies to mouse choroid plexus cell line ECPC-4 by Western blotting. A 29-kDa protein band detected in NP lupus sera was identified as triosephosphate isomerase (TPI). Using Western blotting with TPI, TPI was confirmed as the reactive molecule in sera (6 of 14 samples) and in cerebrospinal fluids (1 of 2 samples) of patients with NP lupus. Enzyme-linked immunosorbent assay with TPI showed that the serum anti-TPI antibody index of 89.8 (SD, 70.1) in NP lupus group was significantly higher than in systemic lupus erythematosus without NP manifestations, 34.6 (29.6); scleroderma, 38.2 (39.9); polymyositis/dermatomyositis, 42.1 (51.5); and control, 31.7 (27.4) groups (p<0.02). Sensitivity, specificity, and positive and negative likelihood ratios of serum anti-TPI antibody index for NP lupus were 42.9%, 94.7%, 8.1%, and 0.6%, respectively. These results suggest that anti-TPI antibodies are closely associated with NP lupus.     

Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors

Summary Monocyte-mediated tumoricidal activity, tumor necrosis factor (TNF) secretion and gene expression were examined in astrocytoma patients, patients with other types of brain tumors (primary or metastatic), and normal individuals. The spontaneous monocyte-mediated tumoricidal activity of either patient group against an astrocytoma cell line was significantly greater than normal. There was no difference between patient groups. When monocytes were stimulated with lipopolysaccharide in vitro, tumoricidal activity increased in all patient groups. Patient monocyte activity tested shortly (48 h) after surgery was not different from that before surgery. Both spontaneous and stimulated monocyte cytocidal activities were tumor-cell-restricted: melanoma and astrocytoma cells were equally susceptible but non-neoplastic glial cells were not affected. Examination of monocyte TNF secretion and mRNA expression indicated that patient activity was comparable to or greater than normal. These results demonstrate that, despite steroid therapy, circulating monocytes in astrocytoma and other brain tumor patients retain intact functional activity.Supported in part by grant CA-49 950 from the National Cancer Institute (B.P.B) and grant 1454-HL from the National Institutes of Health (M.L.E.)     

Identification of autoantibodies associated with systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of antinuclear antibodies. We performed serological analysis of cDNA expression library (SEREX) to identify autoantibodies associated with SLE. The screening of three different cDNA expression libraries with pooled sera of patients with SLE yielded 11 independent clones that reacted with pooled sera of patients with SLE. In this screening, autoantibodies to poly(ADP-ribose) polymerase (PARP), U1snRNP, and galectin-3 were prevalent in the sera of patients with SLE (26/68, 25/68, 12/63, respectively). The frequency of autoantibody to PARP was significantly higher in SLE than that of healthy donors (0/76) (38.2% vs 0%, p<0.00001). The autoantibody to PARP was infrequently detected in the serum of patients with RA (1/50). However, autoantibody to PARP was not found in the sera of patients with other rheumatic diseases including Sjogren's syndrome (0/19), systemic sclerosis (0/18), and polymyositis/myositis (0/37). The frequency of autoantibody to human galectin-3 (12/63) was significantly higher in SLE than that of healthy donors (0/56) (19% vs 0%, p=0.0006). Autoantibody to galectin-3 was not found in the sera of patients with rheumatoid arthritis (0/50), Sjogren's syndrome (0/18), and systemic sclerosis (0/19). Interestingly, autoantibody to galectin-3 was also prevalent in the sera of patients with polymyositis/dermatomyositis (16/37, 43.2%). Further functional characterization of these autoantibodies would be necessary to determine their value as diagnostic markers or to define clinical subsets of patients with SLE. Statistical analysis revealed that the presence of autoantibody to PARP was inversely related with pleurisy, and the presence of autoantibody to galectin-3 related with renal disease.     

Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance

Summary This study has addressed the question of whether there may be some common mechanism underlying the induction or expression of acquired cytokine and drug resistance in a tumor cell line. This study employed the tumor-necrosis-factor(TNF)-sensitive U937 tumor cell line as a model system to determine if selection of a tumor cell variant for cytokine resistance would also result in drug resistance and vice versa. Variants were selected by culturing in the presence of purified recombinant TNF or a mixed-lymphokine-containing supernatant derived from concanavalin-A-stimulated peripheral blood lymphocytes. The resulting variants were resistant not only to TNF, but also to certain chemotherapeutic drugs. The variants were most resistant to colchicine and theVinca alkaloids, requiring drug concentrations 50- to 5000-fold higher to mediate levels of cytotoxicity comparable to that seen with the parental U937. The variants were moderately resistant to cycloheximide, actinomycin D, and mitomycin C. In contrast, these lines were relatively sensitive to doxorubicin or daunomycin. This phenomenon was not unique to U937 cells since we obtained a similar pattern of drug resistance by selecting TNF-resistant variants of the WEHI-164 tumor cell line. The cytokine-selected U937 variants were still lysed by NK cells, although they were somewhat less sensitive than the parental U937. Both variants were relatively resistant to lysis by activated macrophages, probably because of their TNF resistance. In an alternative selection procedure, U937 variants were derived by culturing in the presence of increasing concentrations of colchicine. The resulting variants were relatively resistant to TNF, providing further support for the existence of some common mechanism operating in induction or expression of acquired cytokine and drug resistance. The resistance mechanism apparently does not involve the P glycoprotein since the cytokine-selected U937 variants do not overexpress the mdr gene. This study has demonstrated that selection of TNF-resistant variants results in coexpression of a unique form of drug resistance that is characterized by resistance to microtubule-active drugs but not to the anthracycline antibiotics and is not associated with overexpression of the mdr gene.This work was supported by grant CA 47 669-01 awarded by the National Cancer Institute Nomenclature of variants: U9-LKR, U937 variant selected by lymphokines; U9-TR, U937 variant selected by tumor necrosis factor (TNF); WEHI-TR, WEHI-164 variant selected by TNF